NAAA
TGTX icon

New Age Alpha Advisors’s TG Therapeutics TGTX Stock Holding History

New Age Alpha Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$327K Sell
5,959
-240
-4% -$9.82K 0.01% 687
2026
Q1 		$206K Sell
6,199
-155
-2% -$4.62K 0.01% 615
2025
Q4 		$189K Sell
6,354
-667
-10% -$21.8K 0.01% 618
2025
Q3 		$254K Sell
7,021
-200
-3% -$6.59K 0.01% 588
2025
Q2 		$260K Buy
7,221
+398
+6% +$14.8K 0.01% 575
2025
Q1 		$269K Sell
6,823
-259
-4% -$8.71K 0.01% 594
2024
Q4 		$213K Buy
+7,082
New +$203K 0.01% 653

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

New Age Alpha Advisors's TGTX Position: Q2 2026 in Review

New Age Alpha Advisors reduced its TG Therapeutics (TGTX) stake by 3.9% in Q2 2026, selling an estimated $9.82K and leaving 5,959 shares worth $327K. The position accounts for 0.01% of the portfolio, ranked #687.

New Age Alpha Advisors first reported a position in TGTX in Q4 2024 and has held it in 7 quarters since. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • New Age Alpha Advisors held 5,959 shares of TG Therapeutics worth $327K as of Q2 2026.
  • New Age Alpha Advisors sold 240 TG Therapeutics shares in Q2 2026, an estimated $9.82K.
  • TG Therapeutics made up 0.01% of New Age Alpha Advisors's portfolio in Q2 2026, its #687 holding.
  • New Age Alpha Advisors first reported a position in TG Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on New Age Alpha Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.